Thelansis

 Metachromatic Leukodystrophy (MLD) is a rare lysosomal disease characterized by the accumulation of sulfatides in the central and peripheral nervous system due to deficiency of the enzyme arylsulfatase A, leading to demyelination. This condition is inherited in an autosomal recessive pattern and is caused by mutations in the ARSA and PSAP genes. ·        Metachromatic Leukodystrophy (MLD) is thought to affect between 1 in 40,000 and 1 in 160 000 people worldwide, though the actual prevalence rate is unknown. Thelansis’s “Metachromatic Leukodystrophy (MLD) Market Outlook, Epidemiology , Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metachromatic Leukodystrophy (MLD) treatment modalities opti...